New drug ALK-N001 tested in patients with advanced cancers
NCT ID NCT07529535
First seen Apr 21, 2026 · Last updated May 01, 2026 · Updated 4 times
Summary
This early-phase trial tests a new drug called ALK-N001 in 16 adults with advanced solid tumors (like esophageal, lung, or stomach cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it helps control the disease. The study is currently on hold.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCE SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhejiang Cancer Hospital
Hangzhou, 310022, China
-
Zhongshan Hospital, Fudan University
Shanghai, 200032, China
Conditions
Explore the condition pages connected to this study.